BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18337841)

  • 21. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA.
    Zhang L; Zhang H; Liu W; Wang H; Jia J; Si X; Ren J
    Cell Immunol; 2005 Nov; 238(1):61-6. PubMed ID: 16472793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer.
    Bird RC; Deinnocentes P; Lenz S; Thacker EE; Curiel DT; Smith BF
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):289-304. PubMed ID: 18423623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes.
    Grünebach F; Müller MR; Nencioni A; Brossart P
    Gene Ther; 2003 Mar; 10(5):367-74. PubMed ID: 12601391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells.
    Bontkes HJ; Kramer D; Ruizendaal JJ; Kueter EW; van Tendeloo VF; Meijer CJ; Hooijberg E
    Gene Ther; 2007 Feb; 14(4):366-75. PubMed ID: 17036057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells.
    Ritchie DS; Yang J; Hermans IF; Ronchese F
    Scand J Immunol; 2004 Dec; 60(6):543-51. PubMed ID: 15584965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help.
    Decker WK; Xing D; Li S; Robinson SN; Yang H; Yao X; Segall H; McMannis JD; Komanduri KV; Champlin RE; Shpall EJ
    Vaccine; 2006 Apr; 24(16):3203-16. PubMed ID: 16480795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Appropriate timing of CD40 ligation for RNA-Pulsed DCs to induce antitumor immunity.
    Miura S; Kagamu H; Tanaka H; Yoshizawa H; Gejyo F
    Scand J Immunol; 2008 Apr; 67(4):385-91. PubMed ID: 18282232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J; Glennie MJ; Illidge TM
    Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell responses to multiple antigens presented by RNA-transfected APCs: a possible immunomonitoring tool.
    Bartido SM; Zier K
    Cancer Immunol Immunother; 2004 Feb; 53(2):100-9. PubMed ID: 13680195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.
    Hoogendoorn M; Olde Wolbers J; Smit WM; Schaafsma MR; Jedema I; Barge RM; Willemze R; Falkenburg JH
    Clin Cancer Res; 2005 Jul; 11(14):5310-8. PubMed ID: 16033850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
    Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
    Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner.
    Rodríguez-Pinto D; Moreno J
    Eur J Immunol; 2005 Apr; 35(4):1097-105. PubMed ID: 15756646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient induction and expansion of human alloantigen-specific CD8 regulatory T cells from naive precursors by CD40-activated B cells.
    Zheng J; Liu Y; Qin G; Chan PL; Mao H; Lam KT; Lewis DB; Lau YL; Tu W
    J Immunol; 2009 Sep; 183(6):3742-50. PubMed ID: 19684082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells.
    Hombach A; Muche JM; Gerken M; Gellrich S; Heuser C; Pohl C; Sterry W; Abken H
    Gene Ther; 2001 Jun; 8(11):891-5. PubMed ID: 11423937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis.
    Andreakos E; Rauchhaus U; Stavropoulos A; Endert G; Wendisch V; Benahmed AS; Giaglis S; Karras J; Lee S; Gaus H; Bennett CF; Williams RO; Sideras P; Panzner S
    Arthritis Rheum; 2009 Apr; 60(4):994-1005. PubMed ID: 19333921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfected human dendritic cells to induce antitumor immunity.
    Rughetti A; Biffoni M; Sabbatucci M; Rahimi H; Pellicciotta I; Fattorossi A; Pierelli L; Scambia G; Lavitrano M; Frati L; Nuti M
    Gene Ther; 2000 Sep; 7(17):1458-66. PubMed ID: 11001365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.
    Russo V; Cipponi A; Raccosta L; Rainelli C; Fontana R; Maggioni D; Lunghi F; Mukenge S; Ciceri F; Bregni M; Bordignon C; Traversari C
    J Clin Invest; 2007 Oct; 117(10):3087-96. PubMed ID: 17885685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.